Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr Bart Cornelissen of the CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology who has secured a £200k grant from UK medical research charity, Pancreatic Cancer Research Fund (PCRF).

None

Dr Cornelissen’s project aims to detect pancreatic tumours earlier and evaluate treatments faster using imaging equipment (PET scanners) routinely used in hospitals. He has attached a radioactive atom to a chemotherapy drug and will test whether PET scanners can image the molecule to quickly confirm the presence and position of tumours. He will also test whether using this technique to measure drugs in the body before and after chemotherapy can determine whether the treatment is working.

Read the full press release on the PCRF website.

Read more about Dr Cornelissen's work.

Similar stories

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

OUH agrees long COVID research collaboration with Polarean

The collaboration will look at understanding the long-term effects of COVID-19 through cutting-edge MRI analysis.

Lung abnormalities found in long COVID patients with breathlessness

Researchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.

Eileen Parkes secures Clinical Research Career Development Fellowship

Eileen is awarded funding for her research into the tumour microenvironment